Physician profile
Isabel Rodriguez
NPI 1780780841
$3,627.82
in general payments reported to CMS, 2019-2025
21 companies · $336 in 2025
The $336 reported for 2025 was more than what 77% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $298 · 2020: $588 · 2021: $646 · 2022: $735 · 2023: $685 · 2024: $340 · 2025: $336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,360.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,016.17 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $816.81 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $648.44 | 2019-2025 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $200.84 | 2021-2025 | Xarelto, Invega Sustenna |
| Glaxosmithkline, LLC. | $178.54 | 2022-2025 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $143.94 | 2019-2023 | Belsomra |
| Pfizer INC. | $119.19 | 2022-2025 | |
| Abbvie INC. | $90.71 | 2023-2025 | Ubrelvy, Qulipta |
| Exact Sciences Corporation | $88.48 | 2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.69 | 2021-2024 | Trulance, Xifaxan |
| Vanda Pharmaceuticals INC. | $38.02 | 2020-2021 | |
| Amgen INC. | $35.56 | 2023-2025 | Repatha, Otezla, Otezla |
| Boston Scientific Corporation | $33.82 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.64 | 2023-2024 | Jardiance |
| Phathom Pharmaceuticals, INC. | $30.89 | 2024 | Voquezna |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $21.92 | 2023 | Inspire |
| Medtronic, INC. | $20.42 | 2023 | Closurefast |
| Esperion Therapeutics, INC. | $19.43 | 2021 | |
| Ucb, INC. | $18.84 | 2021 | |
| Shire North American Group INC | $18.52 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.95 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isabel Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.